Opko Ireland Global Holdings, Limited

Ineos Silicas Limited

Cytochroma Development Inc.

Ineos Healthcare Limited

Norman Bryson Roberts

Maurice Webb

Benjamin Joseph Rankin

Benjamin J Rankin

A mixed metal compound for pharmaceutical use is free from aluminum and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.

Metal compounds mixed or sulphated, as phosphate binders

A mixed metal compound for pharmaceutical use is free from aluminium and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.

Metal compounds, mixed or sulphated, as phosphate binders

A non-aluminum containing mixed metal compound for pharmaceutical use, which may, for example, be a mixed metal hydroxy carbonate containing magnesium and iron, and may have a hydrotalcite structure, preferably a non-aged hydrotalcite structure. Other metals, including, for example, calcium, lanthanum and cerium, may also be used. Metal sulphate compounds, especially calcium sulphate, lanthanum sulphate and/or cerium sulphate, compounds are also useful. The mixed metal compounds have a phosphate binding capacity of at least 30%, by weight, based on the test methods 1, 2 or 3, described in the specification, over a pH range from 3 to 7, such as from 2 to 8. The compound is especially useful in the treatment of hyperphosphataemia.

Growing community of inventors

Liverpool, United Kingdom

Norman Bryson Roberts